Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired BioNTech SE (NASDAQ: BNTX) securities.
If you suffered a loss on your BioNTech investment and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: Mar 30 2022 - Oct 13 2023
CASE DETAILS: The filed complaint alleges that BioNTech SE made materially false and/or misleading statements and/or failed to disclose that: (i) BioNTech overstated demand for and/or the commercial prospects of Comirnaty, the COVID-19 vaccine developed by the Company in collaboration with Pfizer ; (ii) the Company and/or Pfizer had accumulated excess inventory of raw materials for Comirnaty, as well as COVID-19 vaccine doses adapted to other, non-XBB.1.5 variants that were produced at risk; (iii) accordingly, BioNTech was at an increased risk of recording significant inventory write-offs and other charges related to Comirnaty; and (iv) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





